Insulet Corporation

When researching Insulet Corporation, analysts typically begin with its Health Care sector positioning and Health Care Equipment industry dynamics. Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

The company reports trailing twelve-month revenue of $761.70M and net income of $91.10M. Key metrics include a return on equity of 7.0%, a debt-to-equity ratio of 1.29.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for PODD to support both active traders and long-term investors.